

P20825.P12

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Yoko AIDA et al.

Group Art Unit: 1646

Serial No : 09/787,437
(National Stage of PCT/JP99/00388)

Examiner: Unknown

Filed : March 27, 2001
(International Filing Date January 29, 1999)

For : APOPTOSIS INDUCING AGENT

**RESPONSE TO PAPER DATED AUGUST 15, 2001
AND
STATEMENT THAT THE CONTENT OF THE PAPER AND
COMPUTER READABLE COPIES ARE THE SAME**

Assistant Commissioner of Patents
Washington, D.C. 20231

Sir:

In response to the Notification of Missing Requirements dated August 15, 2001, (copy submitted herewith) which states that the application does not contain a "Sequence Listing" on paper copy or compact disk, or in computer readable format, reconsideration and withdrawal of the objection to the sequence listing are requested for the reasons discussed below. Inasmuch as the two-month shortened statutory period was originally set in the Office Action to expire on October 15, 2001, Applicants hereby request an extension of time for one month and are concurrently filing a formal Request for Extension of Time, together with all requisite fees therefor. If for any reason the formal Request for Extension of Time is not associated with the file at the Patent and Trademark Office or the extension fee is deficient, this should be considered to be an express request for any necessary extension of time and authorization for the Commissioner to charge any necessary extension of time fee to Deposit Account No. 19-0089.

Rec'd PCT/PTO 15 NOV 2001

P20825.P12

Applicant notes that paper and computer readable forms of nucleotide sequence listings are being filed herewith. In accordance with 37 C.F.R. 1.821(f), the undersigned hereby states that the information recorded in the computer readable form is identical to the written sequence listing. Applicant hereby states that the submission, filed in accordance with 37 C.F.R. 1.821(h), herein does not include new matter.


In view of the above, Applicants respectfully submit that the objection to the sequence listing should be withdrawn.

Applicants further note that the Notification of Missing Requirements stated that Applicants must furnish a surcharge for providing the oath or declaration later than the appropriate 20 or 30 month from the priority date. Applicants submit that the surcharge fee was paid on June 25, 2001 with check number 37685, in response to the Notice of Missing Requirements dated April 24, 2001. A copy of the check and transmittal sheet which accompanied the June 25, 2001 filing, and a date-stamped mailroom receipt is included. Accordingly, no additional fee should be needed. However, if for any reason the objection is maintained, this should be considered to be an authorization for the Commissioner to charge any necessary fee to Deposit Account No. 19-0089.

If there are any comments or questions, the undersigned may be contacted at the below-listed telephone number.

November 14, 2001
GREENBLUM & BERNSTEIN, P.L.C.
1941 Roland Clarke Place
Reston, VA 20191
(703) 716-1191

Respectfully submitted,
Y. AIDA et al.


Bruce H. Bernstein
Reg. No. 29,027
Reg. No. 45,905



U.S. APPLICATION NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
09/787437	AIDA Y	P20825
INTERNATIONAL APPLICATION NO.		
PCT/JP99/00388		
I.A. FILING DATE	PRIORITY DATE	
29 JAN 99	30 SEP 98	
DATE MAILED: 15 AUG 99		

GREENBLUM & BERNSTEIN, P.L.C.
1941 ROLAND CLARKE PLACE
RESTON, VA 20191

**NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE
DISCLOSURES**

Applicant has submitted papers under 35 U.S.C. 371 to enter the national stage in the United States of America. The items indicated below, however, are missing. The period within which to correct the deficiency noted below and avoid abandonment is set forth in the accompanying Notification.

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):

- ☒ The application fails to comply with the requirements of 37 CFR 1.821-1.825.
- ☒ This application does not contain, a "Sequence Listing" as a separate part of the disclosure on paper copy or compact disc, as required by 37 CFR 1.821(c).
- ☒ A copy of the "Sequence Listing" in computer readable format has not been submitted as required by 37 CFR 1.821(e).
- ☐ A copy of the "Sequence Listing" in computer readable form has been submitted. The content of the computer readable form, however, does not comply with the requirements of 37 CFR 1.822 and/or 1.832, as indicated on the attached marked-up copy of the "Raw Sequence Listing."
- ☐ The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).
- ☐ The paper copy or compact disc of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e).
- ☐ Other: _____

APPLICANT MUST PROVIDE:

- ☒ An initial or substitute computer readable form (CRF) of the "Sequence Listing."
- ☐ An initial or substitute paper copy or compact disc of the "Sequence Listing," as well as an amendment directing its entry into the specification.
- ☒ A statement that the contents of the paper or compact disc and the computer readable form are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b) or 1.825(d).

**FOR QUESTIONS REGARDING COMPLIANCE WITH THESE REQUIREMENTS, PLEASE
CALL:**

(703) 308-4216, for Rules interpretation,
(703) 308-4212, for CRF submission help,
(703) 287-0200, for PatentIn software help.

BAC

Telephone: 703 305-3631